From: Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy
Parameter | Gal-1 expression (weak) | Gal-1 expression (strong) | p value |
---|---|---|---|
Age (years) | 0.464 | ||
< 50 | 5 (45.5%) | 10 (29.4%) | |
≥ 50 | 6 (54.5%) | 24 (70.6%) | |
Gender | 0.732 | ||
Female | 5 (45.5%) | 13 (38.2%) | |
Male | 6 (54.5%) | 21 (61.8%) | |
ECOG | 1.000 | ||
0–2 | 8 (72.7%) | 26 (76.5%) | |
3–4 | 3 (27.3%) | 8 (23.5%) | |
Tumor size | 0.897 | ||
< 5 cm | 3 (27.3%) | 7 (20.6%) | |
≥ 5 cm | 2 (18.2%) | 7 (20.6%) | |
Unknown | 6 (54.5%) | 20 (58.8%) | |
OP method | 0.525 | ||
gross total removal | 8 (72.7%) | 17 (50.0%) | |
subtotal removal + biopsy | 3 (27.3%) | 14 (41.2%) | |
unknown | 0 (0%) | 3 (8.8%) | |
RT field | 0.736 | ||
Small | 7 (63.6%) | 19 (55.9%) | |
Whole brain | 4 (36.4%) | 15 (44.1%) | |
EQD2 (Gy) | 0.987 | ||
Mean | 66.36 | 66.38 | |
SEM | 0.67 | 0.46 |